
AstraZeneca Expands Gene Therapy Pipeline with JCR Deal Worth Up to $825M
AstraZeneca’s Alexion Taps JCR Pharmaceuticals for Gene Therapy Capsids in Deal Worth Up to $825M AstraZeneca’s rare disease unit, Alexion, is deepening its partnership with Japan-based JCR Pharmaceuticals through a…












